Canadian vaccine enhancement company ImmunoVaccine has entered into a binding memorandum of understanding to purchase USA-based Immunotope, which specializes in the development of immunotherapy products for cancer and chronic viral infections. Nova Scotia-headquartered ImmunoVaccine said that the acquisition, financial terms of which were not disclosed, will combine its own VacciMax platform with Immunotope's portfolio of therapeutic antigens and discovery platform.
ImmunoVaccine said that the combined company enables the creation of an entire pipeline of proprietary therapeutic cancer and infectious disease specific vaccines, and would initially focus on providing support for ongoing Phase I trials of its range of candidate ovarian and breast cancer vaccines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze